Literature DB >> 17695509

Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.

Masanori Tsujie1, Shoji Nakamori, Shin Nakahira, Yuji Takahashi, Nobuyasu Hayashi, Jiro Okami, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Morito Monden.   

Abstract

BACKGROUND: The purpose of this study was to find a novel biomarker to predict 5-fluorouracil (5-FU) or gemcitabine (2',2'-difluoro-deoxycytidine) sensitivity in pancreatic cancer.
MATERIALS AND METHODS: The relationship between 5-FU and gemcitabine sensitivity and the mRNA levels of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) was investigated using seven types of human pancreatic carcinoma cell line (AsPC1, BxPC3, MiaPaCa-2, PSN1, Panc1, PCI6, and KMP-4). Quantitative mRNA expression was measured by LightCycler. A [3H] gemcitabine cellular uptake assay was performed to examine the inhibition of hENT1 by nitrobenzylmercaptoprine ribonucleoside (NBMPR).
RESULTS: The expression levels of hENT1 mRNA significantly correlated with the IC50 value of 5-FU in all seven lines and also correlated with gemcitabine resistance in six lines (except AsPC1). No significant association was observed between TS or DPD mRNA levels and 5-FU sensitivity. In the PSN1 cells, [3H] gemcitabine uptake via hENT1 was significantly inhibited by NBMPR, and 5-FU sensitivity was significantly increased when the cells were pretreated with NBMPR.
CONCLUSION: Our results suggest that hENT1 plays an important role in 5-FU resistance and that hENT1 mRNA levels might be a useful marker to predict 5-FU sensitivity in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695509

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  22 in total

Review 1.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 2.  Pancreatic biomarkers: could they be the answer?

Authors:  Angela Lamarca; Jaime Feliu
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 3.  Recent studies of 5-fluorouracil resistance in pancreatic cancer.

Authors:  Wei-Bin Wang; Yu Yang; Yu-Pei Zhao; Tai-Ping Zhang; Quan Liao; Hong Shu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Authors:  Chris G Twitty; Oscar R Diago; Daniel J Hogan; Cindy Burrascano; Carlos E Ibanez; Douglas J Jolly; Derek Ostertag
Journal:  Hum Gene Ther Methods       Date:  2015-12-01       Impact factor: 2.396

5.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

6.  Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.

Authors:  Nick Cox; James R Kintzing; Mark Smith; Gerald A Grant; Jennifer R Cochran
Journal:  Angew Chem Int Ed Engl       Date:  2016-06-15       Impact factor: 15.336

Review 7.  Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.

Authors:  Pan Xie; Jun-Luan Mo; Jin-Hong Liu; Xi Li; Li-Ming Tan; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Cell Oncol (Dordr)       Date:  2020-05-30       Impact factor: 6.730

8.  Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.

Authors:  Ken Ohmine; Kei Kawaguchi; Sumio Ohtsuki; Fuyuhiko Motoi; Shinichi Egawa; Michiaki Unno; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2012-03-15       Impact factor: 4.200

9.  Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.

Authors:  Emiko Sugiyama; Nahoko Kaniwa; Su-Ryang Kim; Ryuichi Hasegawa; Yoshiro Saito; Hideki Ueno; Takuji Okusaka; Masafumi Ikeda; Chigusa Morizane; Shunsuke Kondo; Noboru Yamamoto; Tomohide Tamura; Junji Furuse; Hiroshi Ishii; Teruhiko Yoshida; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

10.  Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo.

Authors:  David A Plotnik; Camille Asher; Stephanie K Chu; Robert S Miyaoka; Gregory G Garwin; Brian W Johnson; Tiffany Li; Kenneth A Krohn; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2012-09-15       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.